Principal Investigator: Tuan Pham
Keywords: NASH , Fatty Liver , Probiotic Department: Gastroenterology
IRB Number: 00127915
Specialty: Gastroenterology, Gastroenterology
Sub Specialties: Liver Disease, Hepatology
Recruitment Status: Active, not recruiting

Contact Information

Srinivas Mulamalla
srinivas.mulamalla@hsc.utah.edu
8015852283

Simple Summary

To determine the baseline permeability of the small bowel in patients with fatty liver disease, as compared to normalTo characterize serum inflammatory profiles in patients with fatty liver disease, as compared to normalTo determine whether diet alteration in patients with fatty liver disease will alter small bowel permeability, serum inflammatory profiles, or markers of metabolismTo determine whether administration of probiotic-containing-foods (PCF) in patients with fatty liver disease will alter small bowel permeability, serum inflammatory profiles, or markers of metabolism

Inclusion Criteria

1. Subgroup 1 - 30 patients with stage 0-4 fibrosis, compensated fatty liver disease, varying steatosis levels

2. Subgroup 2 - 30 patients with decompensated cirrhosis

3. Subgroup 3 - 30 normal patients 

Exclusion Criteria

1. Participants unable to eat dairy

2. Participants unwilling to eat yogurt food daily for 6 months

Participant Reimbursement

Yes